Cargando…

Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines

PURPOSE: Tumor Treating Fields (TTFields) are electric fields that disrupt cellular processes critical for cancer cell viability and tumor progression, ultimately leading to cell death. TTFields therapy is approved for treatment of newly-diagnosed glioblastoma (GBM) concurrent with maintenance temoz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fishman, Hila, Monin, Roni, Dor-On, Eyal, Kinzel, Adrian, Haber, Adi, Giladi, Moshe, Weinberg, Uri, Palti, Yoram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232578/ https://www.ncbi.nlm.nih.gov/pubmed/37131108 http://dx.doi.org/10.1007/s11060-023-04308-4

Ejemplares similares

Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
por: Davidi, Shiri, et al.
Publicado: (2022)

In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso
por: Blatt, Roni, et al.
Publicado: (2021)

Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959
por: Davidi, Shiri, et al.
Publicado: (2023)

AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields)
por: Shteingauz, Anna, et al.
Publicado: (2018)

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)
por: Porat, Yaara, et al.
Publicado: (2017)

Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
por: Voloshin, Tali, et al.
Publicado: (2020)

Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells
por: Giladi, Moshe, et al.
Publicado: (2017)

Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs
por: Kirson, Eilon D., et al.
Publicado: (2009)

Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Actin Dynamics
por: Voloshin, Tali, et al.
Publicado: (2020)

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016)

Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model
por: Barsheshet, Yiftah, et al.
Publicado: (2022)

Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro
por: Kapteijn, Maaike Y., et al.
Publicado: (2023)

ET-02 EFFICACY OF THE SALVAGE THERAPY VIA LOMUSTINE AND NIMUSTINE FOR RECURRENT GLIOBLASTOMA WITH TEMOZOLOMIDE RESISTANCE
por: Yamamuro, Shun, et al.
Publicado: (2019)

Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance
por: Yamamuro, Shun, et al.
Publicado: (2021)

Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial
por: Patil, Vijay M., et al.
Publicado: (2022)

TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters
por: Schneiderman, Rosa S, et al.
Publicado: (2010)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis
por: Ballo, Matthew T., et al.
Publicado: (2023)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)
por: Kirson, Eilon D, et al.
Publicado: (2009)

Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
por: Tremont-Lukats, Ivo W., et al.
Publicado: (2019)

Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro
por: Fuchs, Daniel, et al.
Publicado: (2023)

Evaluating the therapeutic effect of tumor treating fields (TTFields) by monitoring the impedance across TTFields electrode arrays
por: Li, Xing, et al.
Publicado: (2022)

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
por: Song, Jie, et al.
Publicado: (2018)

Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis
por: Ren, Xing, et al.
Publicado: (2021)

LMAP-12 TUMOR TREATING FIELDS (TTFIELDS) REAL-WORLD EXPERIENCE IN NEWLY DIAGNOSED GLIOBLASTOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF OVERALL SURVIVAL
por: Ballo, Matthew T, et al.
Publicado: (2023)

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial
por: Weller, J., et al.
Publicado: (2023)

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
por: Larkin, J M G, et al.
Publicado: (2007)

TTFields Prolonged the PFS of Epithelioid Glioblastoma Patient: A Case Report
por: Ding, Yuxuan, et al.
Publicado: (2023)

NovoTTF(™)-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL(™) system user study
por: Chaudhry, Aafia, et al.
Publicado: (2015)

Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood–Brain Barrier In Vitro and In Vivo
por: Salvador, Ellaine, et al.
Publicado: (2022)

Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
por: Das, Sunit, et al.
Publicado: (2020)

Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells
por: Giladi, Moshe, et al.
Publicado: (2015)

Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
por: Kessler, Almuth F., et al.
Publicado: (2018)

First Report of Tumor Treating Fields (TTFields) Therapy for Glioblastoma in Comorbidity with Multiple Sclerosis
por: Kassubek, Rebecca, et al.
Publicado: (2022)

The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts
por: Oberheim-Bush, Nancy Ann, et al.
Publicado: (2022)

Temperature and Impedance Variations During Tumor Treating Fields (TTFields) Treatment
por: Gentilal, Nichal, et al.
Publicado: (2022)

Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine
por: Drazin, Doniel, et al.
Publicado: (2016)

Lomustine Loaded Superparamagnetic Iron Oxide Nanoparticles Conjugated with Folic Acid for Treatment of Glioblastoma Multiforma (GBM)
por: Jafari, Salman, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gi8vonq68dvkqqc03dlnlm7ojp